Education
About Us
Working with TipRanks
Follow Us
Opko Health (OPK)
:OPK
OPK Stock Chart & Stats
$1.53
-$0.03(-1.99%)
At close: 4:00 PM EST
$1.53
-$0.03(-1.99%)
Day’s Range― - ―
52-Week Range$1.11 - $2.04
Previous CloseN/A
Volume574.71K
Average Volume (3M)2.18M
Market Cap
$1.14B
Enterprise ValueN/A
Total Cash (Recent Filing)$271.72M
Total Debt (Recent Filing)$395.74M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Feb 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding793,782,800
10 Day Avg. Volume1,466,492
30 Day Avg. Volume2,176,778
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)0.75
Price to Sales (P/S)1.43
P/FCF Ratio-4.89
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$2.75Price Target Upside79.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOPKO believes that the lab business post-close will achieve cash flow breakeven and positive cash from operations – with further improvements targeted.
Investment OutlookAnalyst maintains an OUTPERFORM investment rating with a price target of $2.25, representing an 89% upside.
Product GrowthRecent prescription trends for NGENLA are positive, and solid growth is expected in the latter half of the year.
Bears Say
Diagnostic Services RevenueDiagnostic services revenue was $101.1M, representing 21.9% YoY decline due to lower clinical test volume as a result of the sale of certain BioReference assets.
Earnings PerformanceReported EPS of ($0.19) were soft versus our $0.15 estimate.
Revenue PerformanceTotal revenue of $156.8 million was a bit light relative to the estimate of $165.3 million.
Opko Health News
OPK FAQ
What was Opko Health’s price range in the past 12 months?
Opko Health lowest stock price was $1.11 and its highest was $2.04 in the past 12 months.
What is Opko Health’s market cap?
Opko Health’s market cap is $1.14B.
When is Opko Health’s upcoming earnings report date?
Opko Health’s upcoming earnings report date is Feb 19, 2026 which is in 112 days.
How were Opko Health’s earnings last quarter?
Opko Health released its earnings results on Oct 29, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.097.
Is Opko Health overvalued?
According to Wall Street analysts Opko Health’s price is currently Undervalued.
Does Opko Health pay dividends?
Opko Health does not currently pay dividends.
What is Opko Health’s EPS estimate?
Opko Health’s EPS estimate is -0.06.
How many shares outstanding does Opko Health have?
Opko Health has 793,782,800 shares outstanding.
What happened to Opko Health’s price movement after its last earnings report?
Opko Health reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Opko Health?
Currently, no hedge funds are holding shares in OPK
Opko Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.75 (79.74% Upside)
$2.75 (79.74% Upside)
Blogger Sentiment
Bullish
OPK Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $891.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.00%
12-Months-Change
Fundamentals
Return on Equity
-13.16%
Trailing 12-Months
Asset Growth
-0.35%
Trailing 12-Months
Company Description
Opko Health
Opko Health, Inc. is a diversified healthcare company focused on the development and commercialization of innovative and proprietary pharmaceuticals, diagnostics, and biologics. The company operates primarily in two segments: pharmaceuticals and diagnostics. Opko's pharmaceutical offerings include products for various therapeutic areas, including urology, endocrinology, and ophthalmology, while its diagnostics segment features advanced laboratory services and diagnostic tests, including the 4Kscore test for prostate cancer risk assessment.
OPK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strategic progress with asset sales and pipeline advancements, but also highlighted financial challenges in terms of revenue decline in diagnostics and increased net loss due to restructuring expenses.View all OPK earnings summariesOPK Stock 12 Month Forecast
Average Price Target
$2.75
▲(79.74% Upside)
Technical Analysis
Ownership Overview
44.29% Insiders
6.47% Mutual Funds
0.13% Other Institutional Investors
38.93% Public Companies and
Individual Investors